CTI BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012 - 1994
Net Income	-92.99	-97.91	-52.45	-40.02	-29.4	-45.02	-52.01	-122.62	-95.99	-49.64	Upgrade
Depreciation & Amortization	1.95	0.53	0.53	0.55	0.59	0.72	0.83	0.99	1.1	1.57	Upgrade
Share-Based Compensation	10.03	4.74	4.32	5.17	6.37	5.75	13.32	14.83	20.2	9.07	Upgrade
Other Operating Activities	-0.18	7.75	5.4	6.49	-17.47	-5.09	-38.83	8.4	32.52	-3.72	Upgrade
Operating Cash Flow	-81.19	-84.89	-42.21	-27.82	-39.82	-39.3	-76.68	-95.2	-39.55	-35.83	Upgrade
Capital Expenditures	0	0	-0.02	0	-0.03	-0.05	-0.14	-0.08	-0.33	-1.53	Upgrade
Acquisitions	-25	0	0	0	0	0	0	0	0	0	Upgrade
Change in Investments	-48.85	12	-9.6	28.13	-30.46	0.01	0	0	0	0	Upgrade
Other Investing Activities	-	-	-	-	-	-	-	-	-0.21	-	Upgrade
Investing Cash Flow	-73.85	12	-9.62	28.13	-30.49	-0.04	-0.14	-0.08	-0.54	-1.53	Upgrade
Share Issuance / Repurchase	63.31	57.03	66.63	0	64.22	-0.03	0	15.15	0	0	Upgrade
Debt Issued / Paid	58.72	41.33	-5.33	-5.33	-0.44	-3.58	-5.45	6.16	3.44	14.5	Upgrade
Other Financing Activities	-2	-0.41	-0.22	-0.28	-0.29	42.58	-1.91	130.71	32.59	44.47	Upgrade
Financing Cash Flow	120.02	97.94	61.07	-5.61	63.49	38.98	-7.37	152.02	36.03	58.97	Upgrade
Net Cash Flow	-35.03	25.05	9.25	-5.3	-6.78	-0.78	-84.18	57.25	-0.71	21.2	Upgrade
Free Cash Flow	-81.19	-84.89	-42.22	-27.82	-39.86	-39.35	-76.82	-95.28	-39.88	-37.36	Upgrade
Free Cash Flow Margin	-150.50%	-	-	-831.75%	-151.61%	-156.47%	-133.82%	-591.22%	-66.39%	-107.75%	Upgrade
Free Cash Flow Per Share	-0.71	-0.94	-0.59	-0.48	-0.71	-1.08	-2.75	-5.06	-2.69	-3.27	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).